San Diego – March 8, 2017 – Cooley advised the underwriters on Global Blood Therapeutics’ $143.8 million shelf-takedown offering of 5,867,347 shares of common stock, which includes the full exercise of the underwriters’ option to purchase up to 765,306 additional shares of common stock.
Cantor Fitzgerald & Co. acted as sole book-running manager for the offering.
Global Blood Therapeutics, which trades on The NASDAQ Global Select Market as “GBT,” is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat blood-based disorders with significant unmet need.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.